JR11 - Oral communication - Marcel NAUMANN

JR11 - Oral communication - Marcel NAUMANN

by Marcel Naumann

Life & Natural Systems Language & Linguistics CBLanguage: reference and generalCBPSpeaking in public: advice and guides
🎙 Marcel Naumann 👥 1K 📅 January 28, 2026 ⏱ 17 min 👁 27 📄 original study 🧭 2026-08-16
Available in: English (current) Français

Keywords

ALSType I InterferoniPSCJAK inhibitorRIG-I

Summary

Marcel Naumann presents research on Type I Interferon (IFN) signaling in ALS, focusing on FUS-mutant models. Using iPSC-derived spinal motor neurons, they observed axonal degeneration and mitochondrial dysfunction. Transcriptomic analysis revealed upregulation of interferon-stimulated genes (ISGs), particularly in P525L mutants. They identified RIG-I as a key mediator, as knockdown reduced ISG expression. They also found that inhibiting mitochondrial transcription with IMT1 reduced ISGs. In microglia, STING signaling appeared more relevant. They tested the JAK inhibitor ruxolitinib, which reduced ISGs in neurons and in a patient with high IFN score, though the patient deteriorated. They propose that IFN signaling is a shared feature of genetic ALS and that JAK inhibition may be a therapeutic strategy.

114 words

Critical Evaluation

Value of the Information & Strength of the Argument

The presentation provides valuable insights into the role of innate immune signaling in ALS, particularly Type I IFN. The argumentation is logical, moving from in vitro models to patient data. The use of multiple approaches (transcriptomics, knockdown, inhibitors) strengthens the evidence. However, some conclusions are based on limited sample sizes and require further validation.

63 words

Title / Content Match

The title accurately reflects the content, which is an oral communication on Type I Interferon signaling in ALS.

Quality & Reliability

7/10

The presentation is based on original research data, with clear methodology and some validation in patient samples. However, it is a conference talk with limited detail on experimental controls and statistical analysis, and some claims are preliminary.

Key Moments

Markers derived by PSI from the transcript: the creator did not define chapters.

Cited Sources

  • RIG-I in sporadic ALS — Mentioned as published evidence for RIG-I in sporadic ALS postmortem tissue.
  • STING in ALS — Mentioned as associated with TDP-43 and C9 ALS, and a Boston paper showing STING in ALS cortex.
  • IMT1 inhibitor — Published inhibitor of mitochondrial polymerase used in experiments.

Concurring Sources

  • RIG-I in sporadic ALS — Mentioned as published evidence for RIG-I in sporadic ALS postmortem tissue.
  • STING in ALS — Mentioned as associated with TDP-43 and C9 ALS, and a Boston paper showing STING in ALS cortex.

Contribution & Novelties

The presentation provides novel evidence that Type I Interferon signaling is a shared feature of genetic ALS, particularly in FUS mutants, and suggests JAK inhibition as a potential therapeutic strategy. It also highlights cell-type-specific differences in signaling pathways.

Pour aller plus loin :

  • Type I interferon signaling in ALS — Review on innate immunity in ALS.
  • JAK-STAT pathway — Overview of the pathway targeted by ruxolitinib.
  • iPSC-derived motor neurons — Protocol and applications in disease modeling.

76 words

Radar Profile

The radar profile shows high scores in quantity of information and technical level, indicating a detailed and specialized presentation. The quality and reliability scores are moderate, reflecting the preliminary nature of some findings.

Reliability 7/10